Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide
Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22.
28 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Camber Energy, Inc.. (NYSE: CEI) jumped 44.2% to $1.3102 after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views
Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also rose, gaining 1.45% to 4,426.68.
ORIC Pharmaceuticals Presents Initial Clinical Data From Phase 1b Trial Of ORIC-101 In Combination With Enzalutamide And Preclinical Data On ORIC-114 at AACR-NCI-EORTC
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced multiple presentations, including initial
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4
The FDA has signed off Oric Pharmaceuticals Inc’s (NASDAQ:ORIC) Investigational New Drug Application (IND) for ORIC-533. The Company can now proceed…
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $53
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $54 to $53.
ORIC Pharmaceuticals Q2 EPS $(0.57) Down From $(0.51) YoY
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.57) per share. This is a 11.76 percent decrease over losses of $(0.51) per share from the same period last year.